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Parafoveolar retinoblastoma regression
with foveal preservation following intra‑arterial
chemotherapy documented on hand‑held
optical coherence tomography in a newborn
Vera Yarovaya, Kareem Sioufi and Carol L. Shields*

Abstract
Background: Optical coherence tomography (OCT) has become an invaluable tool in retinoblastoma management,
providing submillimeter visualization of tumor control following treatment. Herein, we document OCT-detection of a
subtle tumor recurrence, allowing early intervention and achieving foveal microanatomy preservation.
Case presentation: A 3-week-old girl was diagnosed with bilateral familial retinoblastoma, classified as group D in
the right eye (OD) and group B in the left eye (OS), and treated with intravenous chemoreduction. At 6-months follow-up, the right eye was under control, but the left eye revealed a subtle juxtafoveal tumor recurrence, documented
on handheld OCT (HH-OCT) and measuring 2750 µm in diameter and 792 µm in thickness. Treatment with intraarterial chemotherapy (IAC) using 1 cycle of melphalan 5 mg was performed and complete tumor control was achieved,
leaving a flat, concave scar 663 µm from the intact foveola and measuring 2750 µm in diameter and 120 µm in thickness. Foveal microanatomy OS was preserved on HH-OCT. The findings remained stable at 2 years following IAC.
Conclusions: HH-OCT is an important tool in retinoblastoma management. In this case, HH-OCT allowed for early
detection of retinoblastoma recurrence, before foveal invasion. Following treatment with IAC, complete tumor regression was noted and foveal microanatomy remained intact.
Keywords: Eye, Retina, Retinoblastoma, Optical coherence tomography (OCT), Intra-arterial chemotherapy, Foveola,
Fovea
Background
Optical coherence tomography (OCT) has become an
invaluable tool for in vivo evaluation of the microstructure of the retina and choroid. This technology employs
light scatter to create a 2-dimensional cross-sectional
image of the human fundus, initially described by Huang
et al. [1]. With advancements in technology and development of spectral-domain (SD-OCT), high resolution
in vivo evaluation of retinal microanatomy in healthy
and diseased eyes now approaches resolution of tissue histology. The subspecialty of ocular oncology has
*Correspondence: carolshields@gmail.com
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incorporated SD-OCT into practice for the study of the
structure of various retinal, choroidal, optic disc, and
scleral tumors and their relationship to other structures
[2]. Handheld OCT (HH-OCT), a portable, SD-OCT
unit that can be used in the operating room, has become
a crucial diagnostic tool in pediatric retinal diseases as it
provides accurate localization of disease processes and is
completely noninvasive [3]. HH-OCT is also used in the
management of retinoblastoma, providing submillimeter
visualization of tumor development and regression, far
beyond the detection by ophthalmoscopy. In addition,
this technology allows for detection of invisible tumors
[4, 5], and monitoring of foveal microanatomy for visual
prognostication [6].
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Herein, we report the case of a 3-week-old girl with
bilateral familial retinoblastoma treated with systemic
chemoreduction. Tumor recurrence was confirmed on
HH-OCT and was subsequently controlled with intraarterial chemotherapy (IAC). Documentation with HHOCT allowed accurate monitoring of the tumor as well
as the foveola.

Case presentation
A 3-week-old girl, with a family history of maternal
unilateral retinoblastoma, presented for evaluation of
leukocoria right eye (OD). On examination, visual acuity was fix and follow in both eyes (OU) and intraocular
pressures were normal OU. External examination documented obvious leukocoria OD. Fundus evaluation OD
revealed a white macular tumor measuring 16.0 mm in
largest basal dimension and 6.1 mm in thickness, and
with overlying mild vitreous seeding and surrounding
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extensive serous retinal detachment. Fundus evaluation
of the left eye (OS) detected a solitary mass measuring
2.0 mm in basal dimension and 1.0 mm in thickness,
located within 2.0 mm from the foveola. A diagnosis of
bilateral familial retinoblastoma, group D OD and group
B OS, was rendered and treatment with intravenous
chemoreduction (CRD) using vincristine, etoposide, and
carboplatin was initiated. Following therapy with individual tumor consolidation, all retinoblastomas were
regressed.
At 6-months follow-up, the right eye remained under
control, but the left eye revealed a subtle recurrence of
the juxtafoveal tumor (Fig. 1a) and HH-OCT (iVue Optovue, Fremont, CA) revealed an intact macula with adjacent tumor recurrence (Fig. 1b), measuring 2750 µm
in diameter and 792 µm in thickness. The recurrence
was 615 µm from the foveola. Treatment with intraarterial chemotherapy (IAC) using Melphalan 5 mg was

Fig. 1 Documentation of retinoblastoma control using spectral domain hand-held optical coherence tomography (HH-OCT). Following 6 cycles
of intravenous chemotherapy for bilateral retinoblastoma, the left eye demonstrated small dome-shaped, outer retinal tumor recurrence (a) of
2750 µm in basal dimension and 792 µm thickness in the parafoveolar region, documented on HH-OCT (b) and with adjacent shallow subretinal
fluid. The mass was 615 µm from the foveola. Following 1 cycle of intraarterial chemotherapy, the tumor showed complete regression (c) and HHOCT (d) documented a concave scar of 120 µm in thickness and located 663 µm from foveola. There was OCT light transmission through atrophic
retinal pigment epithelial accentuating the underlying thin choroid. The foveola remained intact
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performed and complete tumor control was achieved
with 1 cycle (Fig. 1c), leaving a concave scar of 2750 µm
in diameter and 120 µm in thickness, located 663 µm
from the foveola. In addition, there was underlying choroidal thinning and preservation of the foveal microanatomy documented by HH-OCT OS (Fig. 1d). The findings
remained stable on last follow-up at 2 years following
IAC.

Discussion and conclusions
Chemotherapy is a first-line globe-sparing therapy for retinoblastoma and can be delivered through intravenous,
intraarterial, sub-Tenon fascia, and intravitreal routes
[7]. IAC has assumed a major role in retinoblastoma
management, achieving globe salvage and resolution of
retinal detachment with minimal systemic toxicities [8,
9]. Studies have documented that IAC can be employed
as a primary treatment or secondary (rescue) treatment
for eyes that fail alternative therapies [10]. Overall, IAC
achieves retinoblastoma control with globe salvage in 72%
of eyes as a primary therapy and 62% of eyes when used
as secondary therapy [10]. Our patient had initial treatment with intravenous chemotherapy and was secondarily treated with IAC, achieving immediate tumor control,
and with foveolar preservation, despite the proximity of
the tumor within 615 µm to the foveola.
Imaging of retinoblastoma includes digital wide-field
fundus photography, fluorescein angiography, ultrasonography, and now HH-OCT. In this case we used
the stand-mounted iVue Optovue (Optovue, Freemont,
CA) to capture the tumor. The iVue provides up to 21°
field of view and can be mounted on a wheeled stand
which offers stability when acquiring OCT images during examination under anesthesia. HH-OCT scans using
iVue can be captured with minimal pupillary dilation but
a fully dilated pupil yields better results. HH-OCT provides precise submillimeter tumor documentation within
the retina and even into the choroid [4, 11, 12]. In fact,
HH-OCT can provide detection of “invisible” retinoblastoma, first reported by Saktanasate et al. in which a subclinical tumor was coincidentally captured on HH-OCT
in the macular region, and localized to the outer nuclear
layer [4]. Berry et al. later demonstrated the use of SDOCT to identify subclinical retinoblastoma, estimating
that this technology could allow earlier diagnosis and
treatment with less treatment-related damage to ocular
structures and more careful surveillance [11]. Soliman
et al. evaluated the use of HH-OCT in 63 eyes and found
that in 339 HH-OCT sessions 92% were informative, of
which OCT directed diagnosis in 16% and treatment
in 58% [13]. They also noted that OCT influenced preOCT treatment plans in 15% of all OCT sessions. In this
case, we confirmed clinical suspicion of recurrence using
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HH-OCT documenting a homogenous dome-shaped
intraretinal mass with inner retinal draping over the solid
tumor. We subsequently documented complete tumor
response to IAC with OCT-evidence of concave regression and preservation of the foveola, despite the parafoveolar tumor location.
In our case, tumor recurrence was detected early with
HH-OCT, allowing intervention with IAC for complete
tumor regression and preservation of the foveal microanatomy. In most cases, 3 cycles of IAC are necessary for
tumor control, but given the submillimeter recurrence,
only 1 cycle was necessary to achieve control with no further recurrence on 2-year follow-up.
In summary, HH-OCT is an invaluable tool in retinoblastoma management, providing information that aids
treatment decisions, particularly in juxtafoveal tumors.
The role of HH-OCT in retinoblastoma management
includes detection of subclinical new tumors, monitoring
of tumor regression, detection of small tumor recurrence,
and judgment of foveolar microanatomy with estimation
of visual potential in a preverbal child.
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